Indication
In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations
Medicine details
- Medicine name:
- amivantamab (Rybrevant)
- SMC ID:
- SMC2878
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 08 December 2025
- SMC meeting date:
- 04 November 2025